{"id":391195,"date":"2015-12-18T00:00:00","date_gmt":"2015-12-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorim0315-biopharma-crohns-disease-pharmacor-g7-2015\/"},"modified":"2026-03-31T09:02:32","modified_gmt":"2026-03-31T09:02:32","slug":"pcorim0315-biopharma-crohns-disease-pharmacor-g7-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorim0315-biopharma-crohns-disease-pharmacor-g7-2015\/","title":{"rendered":"Crohn\u2019s Disease | Pharmacor | G7 | 2015"},"content":{"rendered":"<p><em>Last Updated 18 December 2015 <\/em><\/p>\n<p>Treatment options for Crohn\u2019s disease (CD) include conventional, largely generic small molecules and more-potent biological agents, including tumor necrosis factor-alpha (TNF-\u03b1) inhibitors. Despite the clinical and commercial success of the TNF-\u03b1 inhibitors, opportunity remains for agents that can safely and effectively induce and maintain remission in a significant number of patients with moderate to severe CD, especially those refractory to TNF-\u03b1 inhibitors. Indeed, with the launch of vedolizumab (Takeda\u2019s Entyvio) in 2014, physicians have a welcome alternative for TNF-\u03b1 inhibitor-refractory patients. Additional agents in late-stage development include therapies offering a variety of mechanisms of action; prominent candidates include the IL-12\/IL-23 inhibitor ustekinumab (Janssen\u2019s Stelara), the CAM inhibitor etrolizumab (Roche), and oral SMAD7 antisense oligonucleotide mongersen (Celgene\u2019s GED-0301). The IL-12\/IL-23 inhibitor ustekinumab, pending the release of additional Phase III data, has demonstrated efficacy in both TNF-\u03b1 inhibitor-refractory and -naive patients. However, interviewed thought leaders do not expect any of these drugs to displace the TNF-\u03b1 inhibitors as the dominant drug class for moderate to severe CD. The entry of less-expensive biosimilar TNF-\u03b1 inhibitors and the increasingly difficult pricing and reimbursement environment will likely limit emerging agents\u2019 market potential in the CD market.<\/p>\n","protected":false},"template":"","class_list":["post-391195","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391195\/revisions"}],"predecessor-version":[{"id":394318,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391195\/revisions\/394318"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}